MCM2通过抑制p53信号通路促进胆管癌细胞的增殖、迁移和侵袭

doi:10.16288/j.yczz.21-426

遗传 ›› 2022, Vol. 44 ›› Issue (3): 230-244.doi: 10.16288/j.yczz.21-426

MCM2通过抑制p53信号通路促进胆管癌细胞的增殖、迁移和侵袭

王翠玲¹(), 刘信燚¹, 王亚会², 张争¹, 王治东³, 周钢桥^1,³()

1. 军事科学院军事医学研究院辐射医学研究所,蛋白质组学国家重点实验室,国家蛋白质科学中心,北京 102206
2. 军事科学院军事医学研究院生命组学研究所,蛋白质组学国家重点实验室,国家蛋白质科学中心,北京 102206
3. 军事科学院军事医学研究院辐射医学研究所,北京 100850

收稿日期:2021-12-20 修回日期:2022-01-18 出版日期:2022-03-20 发布日期:2022-01-29
通讯作者: 周钢桥 E-mail:1376544094@qq.com;zhougq114@126.com
作者简介:王翠玲,在读硕士研究生,专业方向：放射医学。E-mail: 1376544094@qq.com
基金资助:
国家自然科学基金项目资助(31771397)

MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway

Cuiling Wang¹(), Xinyi Liu¹, Yahui Wang², Zheng Zhang¹, Zhidong Wang³, Gangqiao Zhou^1,³()

1. National Center for Protein Sciences, the State Key Lab of Proteomics, Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 102206, China
2. National Center for Protein Sciences, the State Key Lab of Proteomics, Beijing Institute of Life Omics, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 102206, China
3. Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China

Received:2021-12-20 Revised:2022-01-18 Online:2022-03-20 Published:2022-01-29
Contact: Zhou Gangqiao E-mail:1376544094@qq.com;zhougq114@126.com
Supported by:
Supported by the National Natural Science Foundation of China(31771397)

摘要/Abstract

摘要：

微小染色体维持蛋白2 (minichromosome maintenance protein 2, MCM2)的异常表达与多种恶性肿瘤的发生发展密切相关。为探索MCM2基因对胆管癌细胞肿瘤生物学行为的影响及其潜在的作用机制,本研究首先采用cell counting kit-8 (CCK-8)、平板细胞克隆形成、Transwell和Invasion实验证实,MCM2可促进胆管癌细胞的增殖、迁移和侵袭能力;流式细胞术检测结果显示,MCM2可加快细胞周期进程,抑制细胞凋亡。进一步通过对胆管癌组织RNA测序数据集的分析发现,MCM2基因与p53信号通路的激活显著负相关。采用实时定量PCR (quantitative real time polymerase chain reaction, qRT-PCR)和蛋白质免疫印迹(Western blotting, WB)实验发现,在胆管癌细胞中MCM2可显著下调p53和BAX的mRNA和蛋白表达水平,显著上调BCL2和CCND1的mRNA和蛋白表达水平。采用流式细胞术、qRT-PCR和WB实验进一步证实MCM2基因依赖于p53通路发挥影响胆管癌细胞周期和凋亡的功能。最后,通过分析MCM2的表达水平与胆管癌患者临床预后的相关性发现,MCM2在胆管癌组织中的表达显著高于癌旁组织,且其高表达与患者的不良预后显著相关。综上所述,本研究初步揭示MCM2可能通过抑制p53信号通路促进胆管癌的发生发展,并提示MCM2的高表达与胆管癌的不良预后显著相关,为未来胆管癌新的临床诊治措施的研发提供了理论依据。

关键词: 胆管癌, MCM2, 细胞增殖, 细胞迁移, 细胞侵袭, 细胞周期, 细胞凋亡, p53

Abstract:

The abnormal expressions of minichromosome maintenance protein 2 (MCM2) are closely related to the development of various kinds of cancers. We aimed to explore the functions and potential molecular mechanisms of MCM2 gene in cholangiocarcinoma (CCA) cell lines (Huh28 and RBE). First, the cell counting kit-8 (CCK-8), plate clone formation, transwell and invasion assays showed that MCM2 promotes the proliferation, migration and invasion of CCA cells. Flow cytometry assays showed that MCM2 significantly promotes the cell cycle, and inhibits the apoptosis of CCA cells. Further, by analyzing the RNA sequencing data of cholangiocarcinoma, we found that MCM2 gene is significantly negatively correlated with p53 signaling pathway. Quantitative real time polymerase chain reaction (qRT-PCR) and Western blotting (WB) assays confirmed that MCM2 in CCA cells significantly down-regulated the mRNA and protein expression levels of p53 and BAX, and up-regulated the mRNA and protein expression levels of BCL2 and CCND1. Flow cytometry, qRT-PCR and WB assays confirmed that MCM2 promotes CCA through p53 pathway. Finally, we found that MCM2 is up-regulated in CCA tissues compared to the matched non-tumor cholangiocarcinoma tissues, and the high expressions of MCM2 are significantly associated with the poor clinical outcomes of CCA patients. In conclusion, this study revealed that MCM2 promotes the development of CCA by reducing the p53 pathway, and its high expression levels predict poor prognosis in CCA patients. These results provide a theoretical basis for the development of new clinical diagnosis and treatment of cholangiocarcinoma in the future.

Key words: cholangiocarcinoma, MCM2, proliferation, migration, invasion, cell cycle, apoptosis, p53

王翠玲, 刘信燚, 王亚会, 张争, 王治东, 周钢桥. MCM2通过抑制p53信号通路促进胆管癌细胞的增殖、迁移和侵袭[J]. 遗传, 2022, 44(3): 230-244.

Cuiling Wang, Xinyi Liu, Yahui Wang, Zheng Zhang, Zhidong Wang, Gangqiao Zhou. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway[J]. Hereditas(Beijing), 2022, 44(3): 230-244.

图/表 10

表1

图1

图2

图3

图4

图5

图6

图7

图8

表2

参考文献 30

[1]	Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014,383(9935):2168-2179.
[2]	Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru D. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol, 2019,71(6):1261-1262.
[3]	Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol, 2002,37(6):806-813.
[4]	Guglielmi A, Ruzzenente A, Valdegamberi A, Bagante F, Conci S, Pinna AD, Ercolani G, Giuliante F, Capussotti L, Aldrighetti L, Iacono C. Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients. Eur J Surg Oncol, 2014,40(5):567-575.
[5]	Zhang H, Yang T, Wu MC, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett, 2016,379(2):198-205.
[6]	Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol, 2020,17(9):557-588.
[7]	Weber SM, Ribero D, O'reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford), 2015,17(8):669-680.
[8]	Parker MW, Botchan MR, Berger JM. Mechanisms and regulation of DNA replication initiation in eukaryotes. Crit Rev Biochem Mol Biol, 2017,52(2):107-144.
[9]	Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res, 2005,11(7):2510-2517.
[10]	Guzinska-Ustymowicz K, Pryczynicz A, Kemona A, Czyzewska J. Correlation between proliferation markers: PCNA, KI-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res, 2009,29(8):3049-3052.
[11]	Deng MJ, Sun JJ, Xie SH, Zhen H, Wang YC, Zhong AL, Zhang HQ, Lu RQ, Guo L. Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Mol Med Rep, 2019,20(3):2258-2266.
[12]	Seo J, Seong D, Lee SR, Oh DB, Song J. Post-translational regulation of ARF: perspective in cancer. Biomolecules, 2020,10(8):1143.
[13]	Mercadante A A, Kasi A. Genetics, cancer cell cycle phases. In: Statpearls, Treasure Island (FL): StatPearls Publishing, 2021.
[14]	Lee EW, Seong D, Song J. Cytoplasmic myc is an anti- necroptotic protein. Mol Cell Oncol, 2020,7(6):1817697.
[15]	Yang WX, Pan YY, You CG. CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 may be potential therapeutic targets for hepatocellular carcinoma using integrated bioinformatic analysis. Biomed Res Int, 2019,2019:1245072.
[16]	Zhou GY, Soufan O, Ewald J, Hancock REW, Basu N, Xia JG. Networkanalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res, 2019,47(W1):W234-W241.
[17]	Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan QN, Wang ZC, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, Mcdermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res, 2016,44(W1):W90-W97.
[18]	Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem, 2016,85:375-404.
[19]	El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am, 2019,28(4):587-599.
[20]	Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH. DNA replication licensing and human cell proliferation. J Cell Sci, 2001,114(Pt 11):2027-2041.
[21]	Kristensen TP, Maria Cherian R, Gray FC, Macneill SA. The haloarchaeal MCM proteins: bioinformatic analysis and targeted mutagenesis of the β7-β8 and β9-β10 hairpin loops and conserved zinc binding domain cysteines. Front Microbiol, 2014,5:123.
[22]	Semple JW, Duncker BP. ORC-associated replication factors as biomarkers for cancer. Biotechnol Adv, 2004,22(8):621-631.
[23]	Cheung CHY, Hsu CL, Chen KP, Chong ST, Wu CH, Huang HC, Juan HF. MCM2-regulated functional networks in lung cancer by multi-dimensional proteomic approach. Sci Rep, 2017,7(1):13302.
[24]	Yang J, Xie Q, Zhou H, Chang L, Wei W, Wang Y, Li H, Deng ZX, Xiao YL, Wu JZ, Xu P, Hong XC. Proteomic analysis and NIR-II imaging of MCM2 protein in hepatocellular carcinoma. J Proteome Res, 2018,17(7):2428-2439.
[25]	Forsburg SL. Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev, 2004,68(1):109-131.
[26]	Snyder M, Huang XY, Zhang JJ. The minichromosome maintenance proteins 2-7 (mcm2-7) are necessary for RNA polymerase II (pol II)-mediated transcription. J Biol Chem, 2009,284(20):13466-13472.
[27]	Holland L, Gauthier L, Bell-Rogers P, Yankulov K. Distinct parts of minichromosome maintenance protein 2 associate with histone H3/H4 and RNA polymerase II holoenzyme. Eur J Biochem, 2002,269(21):5192-5202.
[28]	Yankulov K, Todorov I, Romanowski P, Licatalosi D, Cilli K, Mccracken S, Laskey R, Bentley DL. MCM proteins are associated with RNA polymerase II holoenzyme. Mol Cell Biol, 1999,19(9):6154-6163.
[29]	Hubbi ME, Luo WB, Baek JH, Semenza GL. MCM proteins are negative regulators of hypoxia-inducible factor 1. Mol Cell, 2011,42(5):700-712.
[30]	Liu LM, Zhang P, Bai M, He LJ, Zhang L, Liu T, Yang Z, Duan ML, Liu MN, Liu BJ, Du R, Qian Q, Sun SR. p53 upregulated by HIF-1α promotes hypoxia-induced G₂/M arrest and renal fibrosis in vitro and in vivo. J Mol Cell Biol, 2019,11(5):371-382.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

基因名称	引物序列(5ʹ→3ʹ)
MCM2	F: ATGGCGGAATCATCGGAATCC
	R: GGTGAGGGCATCAGTACGC
p53	F: CCTCAGCATCTTATCCGAGTGG
	R: TGGATGGTGGTACAGTCAGAGC
BAX	F: TCAGGATGCGTCCACCAAGAAG
	R: TGTGTCCACGGCGGCAATCATC
BCL2	F: ATCGCCCTGTGGATGACTGAGT
	R: GCCAGGAGAAATCAAACAGAGGC
CCND1	F: TCTACACCGACAACTCCATCCG
	R: TCTGGCATTTTGGAGAGGAAGTG
ACTB	F: AGAGCCTCGCCTTTGCCGAT
	R: CCATCACGCCCTGGTGCCT

特征	TCGA-CHOL		P值	GEO(GSE107943)		P值
特征	高表达(n = 18)	低表达(n = 18)	P值	高表达(n = 15)	低表达(n = 15)	P值
年龄,n(%)
≤60	8(57.1)	6(42.9)	0.73	6(66.7)	3(33.3)	0.43
>60	10(45.5)	12(54.5)		9(42.9)	12(57.1)
性别,n(%)
男	7(43.8)	9(56.2)	0.74	14(58.3)	10(41.7)	0.17
女	11(55.0)	9(45.0)		1(16.7)	5(83.8)
TNM病理分期,n(%)
III+IV	3(37.5)	5(62.5)	0.69	7(77.8)	2(22.2)	0.11
I+II	15(53.6)	13(46.4)		8(38.1)	13(61.9)

MCM2通过抑制p53信号通路促进胆管癌细胞的增殖、迁移和侵袭

MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 10

参考文献 30

相关文章 15

编辑推荐

Metrics

[1]	卢荆澳, 黄春燕, 林芷茵, 唐政, 马宁, 黄志斌. cd99l2基因调控斑马鱼白细胞组织间的迁移机制[J]. 遗传, 2022, 44(9): 798-809.
[2]	秦中勇, 石晓, 曹平平, 褚鹰, 管蔚, 杨楠, 程禾, 孙玉洁. 细胞凋亡反应中NOXA基因启动子发挥增强子功能调节BCL2基因表达[J]. 遗传, 2020, 42(11): 1110-1121.
[3]	张雨, 方玉达. Cohesin结构及功能研究进展[J]. 遗传, 2020, 42(1): 57-72.
[4]	余同露,蔡栋梁,朱根凤,叶晓娟,闵太善,陈红岩,卢大儒,陈浩明. CSN4基因干扰对乳腺癌MDA-MB-231细胞增殖和凋亡的影响[J]. 遗传, 2019, 41(4): 318-326.
[5]	陈家辉, 任学义, 李丽敏, 卢诗意, 程湉, 谭量天, 梁少东, 何丹林, 罗庆斌, 聂庆华, 张细权, 罗文. 转录组测序揭示细胞周期通路参与鸡腹脂沉积[J]. 遗传, 2019, 41(10): 962-973.
[6]	杨阳露, 邹壮志, 袁方, 毛蓓蓓. YAP蛋白T425A位点突变对YAP功能的影响[J]. 遗传, 2017, 39(7): 675-682.
[7]	张潇飞,宋鹤,刘静,张文建,闫晓红,李辉,王宁. 鸡miR-17-92基因簇靶基因ZFPM2的鉴定及功能分析[J]. 遗传, 2017, 39(4): 333-345.
[8]	赵建元,丁寄葳,米泽云,周金明,魏涛,岑山. HIV-1初始传播病毒Vpr基因遗传变异对诱导G₂期阻滞及细胞凋亡的影响[J]. 遗传, 2015, 37(5): 480-486.
[9]	刘同阳,郭海强,朱美妍,黄英泽,贾舒婷,罗瑛,张继虹. 突变型p53与其合成致死基因的研究进展[J]. 遗传, 2015, 37(4): 321-326.
[10]	毕丹,徐扬,逄越,李庆伟. 质膜组分磷脂酰丝氨酸外翻的分子调控机制[J]. 遗传, 2015, 37(2): 140-147.
[11]	胡婉莉,高艾. 长链非编码RNA在血液系统肿瘤中作用的研究进展[J]. 遗传, 2015, 37(11): 1095-1104.
[12]	张蕾, 隋御, 王婷, 李利坚, 李元杰, 金彩霞, 徐方. hMMS2基因对结肠癌细胞耐药逆转的影响[J]. 遗传, 2014, 36(4): 346-353.
[13]	常杨, 穆伟涛, 满朝来. 动物microRNA-181的功能与应用前景[J]. 遗传, 2014, 36(2): 103-110.
[14]	谢树高, 谢银银, 张元亮,黄秋花. miR-145靶向调控DAB2对前列腺癌PC3细胞迁移和侵袭能力的影响[J]. 遗传, 2014, 36(1): 50-57.
[15]	郭晓强，张巧霞，黄卫人，段相林，蔡志明. 染色质重塑因子ARID1A的肿瘤抑制作用[J]. 遗传, 2013, 35(3): 255-261.